RxDoctor Payments Data

Yuankai Lin, MD

Hematology & Oncology · San Francisco, CANPI 1831432988

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $199 of the $249 with a category attached, or 79.9%. 6 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 41.5% of the total. Reporting peaked in 2022 at $148 and has fallen 78.7% since, to $32 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.

$249in general payments, 2019–2025

Across 6 payments — averaging $41.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$103
  • Genentech, Inc.$50
  • AbbVie$32
  • Foundation Medicine, Inc.$26
  • Merck$19
  • Coherus Oncology, Inc.$19
$66,371in research payments, 2019–2025

Across 5 payments — averaging $13,274 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$48K
  • E.r. Squibb & Sons, L.L.C.$18K

What the payments were for

  • Food & beverage$19980%
  • Education$5020%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$249 in reported general payments places this provider in the 15th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Medicare billing

Part B allowed, 2024
$5,183
Medicare patients
52
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in San Francisco

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →